Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Borrego

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Revista Espanola De Cirugia Ortopedica Y Traumatologia|April 16, 2014
[Advances in bone dysplasias]E Borrego, D M Farrington, F J Downey
Health Promotion Practice|February 27, 2020
Increasing the Number of Underrepresented Minority Behavioral Health Researchers Partnering With Underresourced Communities: Lessons Learned From a Pilot Research Project ProgramTheresa H Cruz, Matthew E Borrego, Janet Page-Reeves
The Annals of Pharmacotherapy|August 5, 2016
Assessing the Quality of Economic Evaluations of FDA Novel Drug Approvals: A Systematic ReviewAlex L Woersching, Matthew E Borrego, Dennis W Raisch
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemiaRitesh N Kumar, Dennis W Raisch, Matthew E Borrego
Expert Opinion on Drug Safety|June 8, 2019
Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseasesC Chen, M E Borrego, M H Roberts, et al.
Journal of Medical Economics|August 28, 2019
Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistanceYazan K Barqawi, Matthew E Borrego, Melissa H Roberts, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 15, 2013
A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screeningVishvas Garg, Ning Yan Gu, Matthew E Borrego, et al.
Research in Social & Administrative Pharmacy : RSAP|July 28, 2012
Economic, clinical, and humanistic outcomes (ECHOs) of pharmaceutical care services for minority patients: a literature reviewYan Cheng, Dennis W Raisch, Matthew E Borrego, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 18, 2022
Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost-Benefit AnalysisSarah Glover, Matthew E Borrego, Gretchen M Ray, et al.
Journal of the American Pharmacists Association : Japha|May 23, 2007
How should we measure medication adherence in clinical trials and practice?Matthew E Borrego, Jennifer Short, Gireesh Gupchup, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Revista Espanola De Cirugia Ortopedica Y Traumatologia|April 16, 2014
[Advances in bone dysplasias]E Borrego, D M Farrington, F J Downey
Health Promotion Practice|February 27, 2020
Increasing the Number of Underrepresented Minority Behavioral Health Researchers Partnering With Underresourced Communities: Lessons Learned From a Pilot Research Project ProgramTheresa H Cruz, Matthew E Borrego, Janet Page-Reeves
The Annals of Pharmacotherapy|August 5, 2016
Assessing the Quality of Economic Evaluations of FDA Novel Drug Approvals: A Systematic ReviewAlex L Woersching, Matthew E Borrego, Dennis W Raisch
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemiaRitesh N Kumar, Dennis W Raisch, Matthew E Borrego
Expert Opinion on Drug Safety|June 8, 2019
Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseasesC Chen, M E Borrego, M H Roberts, et al.
Journal of Medical Economics|August 28, 2019
Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistanceYazan K Barqawi, Matthew E Borrego, Melissa H Roberts, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 15, 2013
A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screeningVishvas Garg, Ning Yan Gu, Matthew E Borrego, et al.
Research in Social & Administrative Pharmacy : RSAP|July 28, 2012
Economic, clinical, and humanistic outcomes (ECHOs) of pharmaceutical care services for minority patients: a literature reviewYan Cheng, Dennis W Raisch, Matthew E Borrego, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 18, 2022
Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost-Benefit AnalysisSarah Glover, Matthew E Borrego, Gretchen M Ray, et al.
Journal of the American Pharmacists Association : Japha|May 23, 2007
How should we measure medication adherence in clinical trials and practice?Matthew E Borrego, Jennifer Short, Gireesh Gupchup, et al.
Pageof 5